"The Evaluation of Stimulant Withdrawal" (MARC)

Aaron J. Janowsky

Status and phase

Withdrawn

Phase 2

Conditions

Substance Addiction

Relapse

Anxiety

Treatments

Drug: Coreg

Study type

Interventional

Funder types

Other

NIH

Identifiers

NCT00442923

1P50DA018165 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The purpose of this research study is to determine whether Carvedilol, an FDA approved beta blocker, when administered for an 8-week period to veterans currently undergoing treatment for methamphetamine dependence (1) improves their ability to stay in treatment longer, (2)eases the aversive symptoms that accompany stimulant withdrawal, and (3) increases the time they remain abstinent from methamphetamine.

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Must have entered treatment into the outpatient Clinical Addiction Rehabilitation Section (CARS) through the US Portland Veterans Affairs Medical Center
Must meet the clinical definition for methamphetamine dependence
Self-reported methamphetamine use within 10 days of entering the study
Must be able to understand and sign the consent form

Exclusion criteria

Dependent on any other drug except nicotine, caffeine, marijuana and alcohol
Pregnant or nursing mothers
Psychosis
Dementia
Any serious medical condition that could be aggravated by the study protocol (Allergic reaction, Hypotension, Asthma, Bronchospastic conditions, Angina, Bronchitis, Emphysema, Bradycardia, Heart or blood vessel disease, Diabetes mellitus, Low blood sugar, Kidney disease, Liver disease or Overactive thyroid)
History of withdrawal seizures or delirium tremors
Use of MAO inhibitors within the last two weeks
Considerable hepatocellular injury, including cirrhosis of the liver or liver function test levels higher than 2 times normal